Kerri Fitzgerald

DocwireNews

A study published in Clinical Lymphoma, Myeloma &amp; Leukemia evaluated the safety and efficacy of VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide) in combination with an immunomodulatory agent (IMiD) in patients with relapsed/refractory multiple myeloma (MM) and found that this was an effective and tolerable salvage therapy.Researchers retrospectively analyzed VD-PACE plus an IMiD in 30 patients with relapsed/refractory MM who received one or more cycles of this treatment between January 2012 and April&nbsp;2019.Most patients (n=26; 86%) were double refractory to protease inhibitors and IMiDs, and patients had received a median of three lines prior of therapy.The overall response rate was 67.7%, including 13% of patients who experienced complete remission or better and 13% who experienced a very-good partial response. The researchers called the response &ldquo;impressive&rdquo; for this pretreated population.Median progression-free survival was 11 months, and median overall survival was 26 months. The most common grade &ge;3 adverse events were hematologic events, which the researchers called &ldquo;manageable.&rdquo;

BMI Modifies the Relationship Between Glycemic Status and Asthma Severity in Children

Asthma

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Latest News

Combination Salvage Therapy for Multiple Myeloma Induces “Impressive” Response Rate

Oncology

A study published in Clinical Lymphoma, Myeloma &amp; Leukemia evaluated the safety and efficacy of VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe